Brinretigene vesgedparvovec

维杰哌瑞基

Report date: 2025/07/30 10:29:09

Base Information

Drug NameBrinretigene vesgedparvovec
Drug Alias NameEDIT-101AGN-151587
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionMutated-Centrosomal protein of 290 kDa gene knockout
TargetsCentrosomal protein of 290 kDa
Therapy Area/IndicationsRetinal DiseasesRetinal DegenerationLeber Congenital Amaurosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncAllergan Plc
Inactive CompaniesN/A
Active IndicationsRetinal DiseasesRetinal DegenerationLeber Congenital Amaurosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A